Axsome Therapeutics
AXSM
AXSM
218 hedge funds and large institutions have $2.32B invested in Axsome Therapeutics in 2022 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 56 increasing their positions, 74 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
16% more funds holding
Funds holding: 188 → 218 (+30)
5.46% more ownership
Funds ownership: 63.75% → 69.21% (+5.5%)
24% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 74
Holders
218
Holding in Top 10
11
Calls
$179M
Puts
$133M
Top Buyers
| 1 | +$135M | |
| 2 | +$84.7M | |
| 3 | +$70.6M | |
| 4 |
VA
VR Adviser
New York
|
+$51.7M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$35.5M |
Top Sellers
| 1 | -$67M | |
| 2 | -$44.1M | |
| 3 | -$43.7M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$23.2M |
| 5 |
Goldman Sachs
New York
|
-$19.5M |